Results 11 to 20 of about 78,184 (307)

Structure of BTK kinase domain with the second-generation inhibitors acalabrutinib and tirabrutinib.

PLoS ONE, 2023
Bruton's tyrosine kinase (BTK) is the target of the therapeutic agent, Ibrutinib, that treats chronic lymphocyte leukemia (CLL), mantle cell lymphoma (MCL) and other B cell malignancies. Ibrutinib is a first in class, covalent BTK inhibitor that limits B-
David Y Lin, Amy H Andreotti
doaj   +3 more sources

Combining BTK inhibitors with BCL2 inhibitors for treating chronic lymphocytic leukemia and mantle cell lymphoma

Biomarker Research, 2022
The advent of BTK inhibitors has changed the treatment of patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The first-in-class BTK inhibitor ibrutinib has shown remarkable therapeutic effects and manageable toxicities in ...
Jing Zhang, Xueying Lu, Jianyong Li, Yi Miao   +3 more
doaj   +2 more sources

Salt Stress Alleviation in Triticum aestivum Through Primary and Secondary Metabolites Modulation by Aspergillus terreus BTK-1

Frontiers in Plant Science, 2022
We report the growth promoting potential in wheat under saline conditions by an endophytic fungus Aspergillus terreus BTK-1. The isolated BTK-1 from the root of Chenopodium album was identified as Aspergillus terreus through 18S rDNA sequence analysis ...
Muhammad Ikram Khan, Niaz Ali, Gul Jan, Muhammad Hamayun, Farzana Gul Jan, Amjad Iqbal, Anwar Hussain, In-Jung Lee   +7 more
doaj   +2 more sources

Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia.

New England Journal of Medicine, 2023
BACKGROUND Patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) have poor outcomes after the failure of covalent Bruton's tyrosine kinase (BTK) inhibitor treatment, and new therapeutic options are needed.
A. Mato, J. Woyach, Jennifer R. Brown, P. Ghia, K. Patel, T. Eyre, T. Munir, E. Lech-Maranda, N. Lamanna, C. Tam, Nirav N Shah, Catherine C Coombs, C. Ujjani, B. Fakhri, C. Cheah, M. Patel, A. Alencar, Jonathon B. Cohen, J. Gerson, I. Flinn, Shuo Ma, D. Jagadeesh, J. Rhodes, F. Hernandez-Ilizaliturri, P. Zinzani, J. Seymour, M. Balbas, B. Nair, P. Abada, Chunxiao Wang, A. Ruppert, Denise Y Wang, D. Tsai, W. Wierda, W. Jurczak   +34 more
semanticscholar   +1 more source

Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor

Blood, 2023
Key Points • Pirtobrutinib is a potent, noncovalent (reversible), highly selective inhibitor of BTK and C481-mutant BTK.• Pirtobrutinib is efficacious in B-cell models in vitro and in vivo, including patient-derived CLL cells.
E. Gómez, K. Ebata, Hetal S Randeria, M. Rosendahl, E. P. Cedervall, T. Morales, Lauren M. Hanson, Nicholas E. Brown, Xueqian Gong, J. Stephens, Wenjuan Wu, Isabel Lippincott, Karin S Ku, R. Walgren, P. Abada, J. Ballard, C. Allerston, B. Brandhuber   +17 more
semanticscholar   +1 more source

Cardiovascular Toxicities of BTK Inhibitors in Chronic Lymphocytic Leukemia

JACC CardioOncology, 2023
Over the past decade, the treatment landscape of chronic lymphocytic leukemia (CLL) has dramatically changed, shifting from cytotoxic chemotherapy to targeted therapies.
Cooper J. Quartermaine, S. Ghazi, Aneeq Yasin, F. Awan, M. Fradley, Tracy E. Wiczer, Sujay Kalathoor, M. Ferdousi, Satyam Krishan, Alma Habib, A. Shaaban, Onaopepo Kola-Kehinde, A. Kittai, K. Rogers, M. Grever, P. Ruz, S. Bhat, Tyler Dickerson, John C. Byrd, J. Woyach, Daniel Addison   +20 more
semanticscholar   +1 more source

CXCR4-BTK axis mediate pyroptosis and lipid peroxidation in early brain injury after subarachnoid hemorrhage via NLRP3 inflammasome and NF-κB pathway

Redox Biology, 2023
C-X-C chemokine receptor type 4 (CXCR4) is critical for homeostasis of the adaptive and innate immune system in some CNS diseases. Bruton's tyrosine kinase (BTK) is an essential kinase that regulates inflammation in immune cells through multiple ...
Chengli Liu, Kun Yao, Q. Tian, Yujia Guo, Guijun Wang, Pei-Na He, Jianfeng Wang, Jian Wang, Zhangjie Zhang, Mingchang Li   +9 more
semanticscholar   +1 more source

BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib

Blood Advances, 2023
Key Points • One-third of patients with CLL relapsing on ibrutinib do not carry BTK/PLCG2 mutations, even with a 0.1% sensitivity.• Additional mechanisms, such as del(8p), EGR2 and NF-κB pathway mutations, may be cooperating in determining progression on
S. Bonfiglio, L. Sutton, V. Ljungström, A. Capasso, Tatjana Pandzic, Simone Weström, H. Foroughi-Asl, A. Skaftason, A. Gellerbring, Anna Lyander, F. Gandini, G. Gaidano, L. Trentin, L. Bonello, G. Reda, Csaba Bödör, N. Stavroyianni, C. Tam, R. Marasca, F. Forconi, P. Panayiotidis, I. Ringshausen, O. Jakšić, A. Frustaci, S. Iyengar, M. Coscia, S. Mulligan, L. Ysebaert, V. Strugov, C. Pavlovsky, R. Walewska, A. Österborg, D. Cortese, P. Ranghetti, P. Baliakas, K. Stamatopoulos, L. Scarfò, R. Rosenquist, P. Ghia   +38 more
semanticscholar   +1 more source

Comparative Analysis of BTK Inhibitors and Mechanisms Underlying Adverse Effects

Frontiers in Cell and Developmental Biology, 2021
The cytoplasmic protein-tyrosine kinase BTK plays an essential role for differentiation and survival of B-lineage cells and, hence, represents a suitable drug target.
H. Y. Estupiñán, A. Berglöf, R. Zain, C. I. Smith   +3 more
semanticscholar   +1 more source

BTK signaling - a crucial link in the pathophysiology of chronic spontaneous urticaria.

Journal of Allergy and Clinical Immunology, 2023
Chronic spontaneous urticaria (CSU) is an inflammatory skin disorder that manifests with itchy wheals, angioedema, or both for >6 weeks. Mast cells (MCs) and basophils are the key pathogenic drivers of CSU; their activation results in histamine and ...
J. Bernstein, Marcus Maurer, S. Saini
semanticscholar   +1 more source